

Please type a plus sign (+) inside this box —

DECO 5 2005
PATENT AND TRADEMARK OFFICE
persons are required to record the
mark in the office.

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

PATENT AND TRADEMARK OFFICE: U.S. DEPARTMENT OF COMMERCE
a collection of information unless it displays a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|--|---|------------------------|---------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | Application Number | 10/790,182 |
| | | Filing Date | March 2, 2004 |
| | | First Named Inventor | YEDGAR, Saul |
| | | Group Art Unit | 1621 |
| | | Examiner Name | O'Sullivan, Peter G |
| Sheet | 1 | of | 3 |
| | | Attorney Docket Number | |
| | | P-2507-US2 | |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

**Date
Considered**


Jan 2001

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

| | | | | | |
|---|---|----|---|------------------------|----------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/790,182 |
| | | | | Filing Date | March 2, 2004 |
| | | | | First Named Inventor | YEDGAR, Saul |
| | | | | Group Art Unit | 1621 |
| | | | | Examiner Name | O'Sullivan, Peter G. |
| Sheet | 2 | of | 3 | Attorney Docket Number | P-2507-US2 |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|--|--|--|--------------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ² |
| 110 | N | ALBINI, A, IWAMOTO, Y, KLEINMAN, HK, MARTIN, GR, AARONSON, SA, KOZLOWSKI, JM AND MCEWAN. RN (1987) "A rapid in vitro assay for quantitating the invasive potential of tumor cells" <i>Cancer Res</i> 47(12):3239-45 | | | <input type="checkbox"/> |
| | O | BALSINDE, J, BALBOA, MA, YEDGAR, S AND DENNIS, EA (2000) "Group V phospholipase A(2)-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D(1) macrophages" <i>J Biol Chem</i> 275(7):4783-6 | | | <input type="checkbox"/> |
| | P | BECK, G, YARD, BA, SCHULTE, J, OBERACKER, R, VAN ACKERN, K, VAN DER WOUDE, FJ, KRIMSKY, M, KASZKIN, M AND YEDGAR, S (2002) "Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane" <i>Br J Pharmacol</i> 135(7):1665-74. | | | <input type="checkbox"/> |
| | Q | CABANAS, C AND HOGG, N (1993) "Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule 1" <i>Proc Natl Acad Sci U S A</i> 90(12):5838-42. | | | <input type="checkbox"/> |
| | R | CHEN, WM, SORIA, J, SORIA, C, KRIMSKY, M AND YEDGAR, S (2002) "Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2)" <i>FEBS Lett</i> 522(1-3):113-8 | | | <input type="checkbox"/> |
| | S | DAN, P, DAGAN, A, KRIMSKY, M, PRUZANSKI, W, VADAS, P AND YEDGAR, S (1998) "Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers" <i>Biochemistry</i> 37(17):6199-204 | | | <input type="checkbox"/> |
| | T | GREAVES, MW AND CAMP RD (1988) "Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin" <i>Arch Dermatol Res</i> 280:S33-41 | | | <input type="checkbox"/> |
| | U | KRIMSKY, M, DAGAN, A, APTEKAR, L, LIGUMSKY, M AND YEDGAR, S (2000) "Assessment of intestinal permeability in rats by permeation of inulin-fluorescein" <i>J Basic Clin Physiol Pharmacol</i> 11(2):143-53 | | | <input type="checkbox"/> |
| | V | KRIMSKY, M, YEDGAR, S, APTEKAR, L, SCHWOB, O, GOSHEN, G, GRUZMAN, A, SASSON, S AND LIGUMSKY, M (2003) "Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor" <i>Am J Physiol Gastrointest Liver Physiol</i> 285(3):G586-92 | | | <input type="checkbox"/> |
| | W | MARGOLIS-NUNNO, H, BEN-HUR, E, GOTTLIEB, P, ROBINSON, R, OETJEN, J AND HOROWITZ, B (1998) "Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates" <i>Transfusion</i> 38(8):743-50. | | | <input type="checkbox"/> |
| | X | MURTHY, SN, COOPER, HS, SHIM, H, SHAH, RS, IBRAHIM, SA AND SEDERGRAN, DJ (1993) "Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin" <i>Dig Dis Sci</i> 38(9):1722-34 | | | <input type="checkbox"/> |
| 110 | Y | OKAYASU, I, HATAKEYAMA, S, YAMADA, M, OHKUSA, T, INAGAKI, Y AND NAKAYA, R (1990) "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice" <i>Gastroenterology</i> 98(3):694-702 | | | <input type="checkbox"/> |

| | | | |
|--------------------|--------------|-----------------|-----------------|
| Examiner Signature | <i>✓-D'A</i> | Date Considered | <i>for 2006</i> |
|--------------------|--------------|-----------------|-----------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Please type a plus sign (+) inside this box →

DEC 06 2005

U.S. PATENT & TRADEMARK OFFICE

PTO/SB/08A (10-98)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

| Substitute for form 1449B/PTO | | | | Complete if Known | |
|--|---|----|---|------------------------|---------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/790,182 |
| | | | | Filing Date | March 2, 2004 |
| | | | | First Named Inventor | YEDGAR, Saul |
| | | | | Group Art Unit | 1621 |
| (use as many sheets as necessary) | | | | Examiner Name | O'Sullivan, Peter G |
| Sheet | 3 | of | 3 | Attorney Docket Number | P-2507-US2 |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-------------------------|---|--------------------------|-----------------|
| Examiner Initials* | Cite No ¹ | Includé name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | ² |
| 13 | Z | SCHMIEL, DH AND MILLER, VL (1999) "Bacterial phospholipases and pathogenesis" <u>Microbes Infect</u> 1(13):1103-12 | <input type="checkbox"/> | |
| 6 | AA | SCHNITZER, E. DAGAN, A, KRIMSKY, M, LICHTENBERG, D, PINCHUK, I, SHINAR, H AND YEDGAR, S (2000) "Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation" <u>Chem Phys Lipids</u> 104(2):149-60 | <input type="checkbox"/> | |
| | BB | SCHNITZER, E. PINCHUK, I, FAINARU, M, LICHTENBERG, D AND YEDGAR, S (1998) "LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro" <u>Free Radic Biol Med</u> 24(7-8):1294-303 | <input type="checkbox"/> | |
| | CC | SCHNITZER, E, YEDGAR, S, DANINO, D, TALMON, Y AND LICHTENBERG, D (1999) "The Interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and its effect on copper induced LDL oxidation" <u>Biophysical Journal</u> 76(1): Part 2 | <input type="checkbox"/> | |
| ↓ | DD | YARD, BA, YEDGAR, S, SCHEELE, M, VAN DER WOUDE, D, BECK, G, HEIDRICH, B, KRIMSKY, M, VAN DER WOUDE, FJ AND POST, S (2002) "Modulation of IFN-gamma-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid" <u>Transplantation</u> 73(6):984-92 | <input type="checkbox"/> | |
| 13 | EE | YEDGAR, S, LICHTENBERG, D AND SCHNITZER, E (2000) "Inhibition of phospholipase A(2) as a therapeutic target" <u>Biochim Biophys Acta</u> 1488(1-2):182-7 | <input type="checkbox"/> | |
| | | | <i>13.1</i> | <i>Jan 2006</i> |
| | | | | |
| | | | | |
| | | | | |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|-----------------------------|-----------------|-------------------------------|------------|
| Substitute for form 1449A/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 91397 | | |
| <i>(use as many sheets as necessary)</i> | | Filing Date | August 23, 1989 | | |
| | | First Named Inventor | | | |
| | | Group Art Unit | | | |
| | | Examiner Name | | | |
| Sheet | 1 | of | 2 | Attorney Docket Number | P-57917-IL |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| | | | |
|--------------------|-------|-----------------|-----------|
| Examiner Signature | V. JN | Date Considered | June 2006 |
|--------------------|-------|-----------------|-----------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance. Considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patent, Mail Code 2000, Washington, DC 20231.

| | | | | | |
|--|---|----|---|------------------------|-----------------|
| Substitute for form 1449B/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 91397 |
| Sheet | 2 | of | 2 | Filing Date | August 23, 1989 |
| | | | | First Named Inventor | |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| | | | | Attorney Docket Number | P-57917-IL |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|--|--|--|--------------------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | T ² |
| HP | D | Group V Phospholipase A ₂ -mediated Oleic Acid Mobilization in Lipopolysaccharide-stimulated P388D ₁ Macrophages; BALSINDE Jesus, BALBOA Maria A., YEDGAR Saul, and DENNIS Edward A., The Journal of Biological Chemistry, Vol 275, Feb 18 pp4783-4786 | | | <input type="checkbox"/> |
| | E | Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane BECK, G. Ch, YARD B.A. SCHULTE J., OBERACKER, R, VAN ACKERN K, VAN DER WOUDE F.J, KRIMSKY M, KASZKIN M and YEDGAR Y.; British Journal of Pharmacology (2002) 135, 1665-1674 | | | <input type="checkbox"/> |
| | F | Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A ₂ ; CHEM, W.M, SORIA J, CORIA C, KRIMSKY M and YEDGAR S.; FEBS 26215 letters 522 (2002) 113-118 | | | <input type="checkbox"/> |
| | G | Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lips to oxidation; SCHNITZER Edit, DAGAN Arie, KRIMSKY Miron, LICHTENBERG Dov, PINCHUK Ilya, SHINAR Hadassa, YEDGAR Saul; CPL 104 (2000) 149-160 | | | <input type="checkbox"/> |
| | H | Inhibition of phospholipase A ₂ as a therapeutic target; YEDGAR Saul, LICHTENBERG Dov, SCHNITZER Edit, BBA Biochimica et Biophysica Acta 1488 (2000) 182-187 | | | <input type="checkbox"/> |
| ↓ | I | Modulation of IFN-GAMMA-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid; YARD Benito A., YEDGAR Saul, SCHEELE Martin, VAN DER WOULDE Diane, BECK Grietje, HEIDRICH Barbel, KRIMSKY Miron, VAN DER WOULDE Fokko J, and POST Stefan TRANSPLANTATION Vol 73, 984-992, No. 6, March 27, 2002 | | | <input type="checkbox"/> |
| HP | J | Inhibition of Type I and Type II Phospholipase A ₂ by Phosphatidyl-Ethanolamine Linked to Polymeric Carriers; PHYLLIS Dan, ARIE Dagan, MIRON Krimsky, WALDEMAR Pruzanski, PETER Vadas, and Saul Yedgar. Biochemistry 1998, 37, 6199-6204 | | | <input type="checkbox"/> |

| | | | |
|--------------------|-----------|-----------------|-----------------|
| Examiner Signature | <i>HP</i> | Date Considered | <i>Jan 2006</i> |
|--------------------|-----------|-----------------|-----------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.